Bluejay Diagnostics, Inc.
Business
Bluejay Diagnostics is a clinical-stage medical diagnostics company developing Symphony, a rapid point-of-care immunoassay platform for critical care biomarker measurement. The lead product is the Symphony IL-6 test, designed to measure interleukin-6 in whole blood within approximately 20 minutes for sepsis risk stratification in ICU and ER settings. The company is conducting the SYMON-II pivotal clinical trial to support a planned FDA 510(k) submission.
Summary from 10-K filed 2026-03-06
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 3 | 3 | 6 | 4 | 1 | |
| General and administrative | 4 | 4 | 4 | 5 | 2 | |
| Sales and marketing | — | 8,297 | 283,443 | 451,421 | 289,726 | |
| Total operating expenses | 7 | 7 | 10 | 9 | 3 | |
| Operating loss | −7 | −7 | −10 | −9 | −3 | |
| Interest expense | −839 | −823,028 | — | — | — | |
| Interest income | 97,559 | 145,823 | 164,900 | — | — | |
| Other income, net | 7,769 | 129,027 | 192,429 | 168,464 | — | |
| Total other income (expense), net | 104,489 | −548,178 | 357,329 | 20,828 | −258,135 | |
| Net loss | −7 | −8 | −10 | −9 | −3 | |
| Deemed dividend on warrant modification | — | 13 | — | — | — | |
| Net loss applicable to common stockholders | −7 | −21 | −10 | — | — | |
| Net Loss per share to common stockholders Basic (in Dollars per share) | −15.25 | −456.75 | −3,631 | −9.22 | −0.41 | |
| Net Loss per share to common stockholders Diluted (in Dollars per share) | −15.25 | −456.75 | −3,631 | −9.22 | −0.41 | |
| Weighted average common shares outstanding Basic (in Shares) | 449,043 | 45,848 | 2,741 | 1 | 9 | |
| Weighted average common shares outstanding Diluted (in Shares) | 449,043 | 45,848 | 2,741 | 1 | 9 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 4 | 2 | 10 | 19 | |
| Prepaid expenses and other current assets | 275,957 | 596,938 | 747,263 | 2 | 2 | |
| Assets held for sale | 22,770 | — | — | — | — | |
| Total current assets | 5 | 5 | 3 | 12 | 21 | |
| Property and equipment, net | 2 | 2 | 1 | 1 | 337,366 | |
| Operating lease right-of-use assets | 113,289 | 209,788 | 333,267 | 465,514 | — | |
| Other non-current assets | 7,905 | 35,257 | 28,663 | 35,211 | 21,019 | |
| Total assets | 7 | 7 | 5 | 14 | 21 | |
| Accounts payable | 214,255 | 145,122 | 491,474 | 635,818 | 295,778 | |
| Operating lease liability, current | 100,000 | 113,260 | 162,990 | 168,706 | — | |
| Accrued expenses | 804,942 | 551,986 | 1 | 835,730 | 341,384 | |
| Total current liabilities | 1 | 810,368 | 2 | 2 | 637,162 | |
| Operating lease liability, non-current | 20,211 | 108,989 | 189,987 | 323,915 | — | |
| Other non-current liabilities | 4,540 | 8,567 | 12,321 | 15,823 | — | |
| Total liabilities | 1 | 927,924 | 2 | 2 | 637,162 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 604,534 and 138,503 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 60 | 14 | — | 101 | 2,011 | |
| Additional paid-in capital | 47 | 40 | 30 | 29 | — | |
| Accumulated deficit | −42 | −35 | −27 | −17 | −8 | |
| Total stockholders equity | 6 | 6 | 3 | 12 | 20 | |
| Total liabilities and stockholders equity | 7 | 7 | 5 | 14 | 21 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 74,182 | 75,618 | 648,708 | 156,598 | — | |
| Stock-based compensation expense | 6 | 20,094 | 189,245 | 433,004 | — | |
| Amortization of right-of-use asset | 96,499 | 123,479 | 132,247 | 149,770 | — | |
| Non-cash interest expense for note payable | — | 307,563 | — | — | — | |
| Write-off and impairment of property and equipment | 42,937 | 3,411 | 1,787 | 237,309 | — | |
| Prepaid expenses and other current assets | 333,881 | 150,325 | 926,217 | −40,772 | — | |
| Deferred offering costs | — | 265,081 | — | — | — | |
| Other non-current assets | 27,352 | −6,594 | 6,548 | −14,192 | −21,019 | |
| Accounts payable | 69,133 | −346,352 | −235,760 | 298,881 | −79,150 | |
| Accrued expenses and other current and non-current liabilities | 150,918 | −695,653 | −30,279 | 336,620 | — | |
| Net cash used in operating activities | −6 | −8 | −8 | −8 | −4 | |
| Purchase of property and equipment | −173,735 | −306,783 | −704,166 | −1 | −23,947 | |
| Net cash used in investing activities | −173,735 | −306,783 | −704,166 | −1 | −23,947 | |
| Proceeds from issuance of common stock, gross | 8 | 12 | 2 | — | — | |
| Payment for issuance costs of common stock | −1 | −2 | −413,544 | — | — | |
| Proceeds from issuance of notes payable | — | 2 | — | — | — | |
| Repayment of notes payable | — | −2 | — | — | −289,617 | |
| Proceeds from exercise of Class D warrants | — | 558 | — | — | 9,079 | |
| Fractional shares adjustment for reverse stock split | — | −395 | — | — | — | |
| Payment of finance lease | −4,027 | −3,754 | −4,807 | −801 | — | |
| Net cash provided by financing activities | 7 | 10 | 1 | 8,075 | 23 | |
| Net increase in cash and cash equivalents | 862,930 | 2 | −8 | −9 | — | |
| Fair value of common stock issued in connection with notes payable | — | 307,563 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Bluejay Diagnostics, Inc.'s CIK number?
Bluejay Diagnostics, Inc.'s SEC CIK number is 0001704287 (1704287). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Bluejay Diagnostics, Inc.'s SEC filings?
All of Bluejay Diagnostics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Bluejay Diagnostics, Inc. last report earnings?
Bluejay Diagnostics, Inc. (BJDX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-053295). This is Bluejay Diagnostics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Bluejay Diagnostics, Inc.'s most recent earnings 8-K?
Bluejay Diagnostics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001213900-26-053295. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Bluejay Diagnostics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →